Tag: Biosense Webster

BIOSENSE WEBSTER ANNOUNCES FIRST PATIENTS ENROLLED IN POST-MARKET APPROVAL STUDY FOR ITS NOVEL TAG-INDEX GUIDED SOFTWARE

IRVINE, Calif., SEPTEMBER 26 – Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has received approval from the U.S. Food and Drug Administration (FDA) for its VISITAG SURPOINT External Processing Unit and enrollment has begun […]

BIOSENSE WEBSTER, INC. ANNOUNCES FIRST PATIENT TREATED IN STUDY OF MULTI-ELECTRODE RADIOFREQUENCY BALLOON CATHETER

Multicenter Study to Evaluate Balloon Ablation Catheter for Safety and Effectiveness in Achieving Pulmonary Vein Isolation in Treatment of Paroxysmal Atrial Fibrillation IRVINE, CA, MARCH 15 – Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, […]

PATIENT ENROLLMENT COMPLETED IN U.S. IDE STUDY OF THERMOCOOL SMARTTOUCH® SF CATHETER FOR TREATMENT OF PERSISTENT ATRIAL FIBRILLATION

IRVINE, CA, — March 13, 2018 — Johnson & Johnson Medical Devices Companies* announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has completed patient enrollment in its U.S. Investigational Device Exemption (IDE) study of the THERMOCOOL SMARTTOUCH® SF Catheter. The prospective, […]

First Patient Enrolled in U.S. IDE Study To Evaluate the Potential of New Device To Reduce Stroke Risk in Atrial Fibrillation Patients

IRVINE, Calif., Jan. 11, 2018 /PRNewswire/ — Johnson & Johnson Medical Devices Companies* today announced that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, enrolled the first patient in the WaveCrest® Investigational Device Exemption (IDE) Trial. The study will evaluate the safety and effectiveness of the WaveCrest® Left Atrial […]

Biosense Webster Launches CARTO® 3 System CARTO VISITAG™ Module with Ablation Index, designed to help Electrophysiologists standardize and simplify the treatment of Atrial Fibrillation

DIAMOND BAR, California, March 22, 2017 /PRNewswire/ — Biosense Webster, a Division of Johnson & Johnson Medical NV/SA, a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced today the launch of the CARTO VISITAG™ Module with Ablation Index, a new technology providing visual indication based on the […]